This time is just another mAb:
Shares of Peregrine Pharmaceuticals Inc. sank Thursday after the drug developer said it will stop studying a treatment combination involving its potential lung cancer drug bavituximab.
THE SPARK: The Tustin, Calif., company said a combination of bavituximab, carboplatin and a chemotherapy drug labeled paclitaxel did not produce a meaningful enough difference in overall survival in patients compared with carboplatin and paclitaxel alone. The company had just completed an analysis of data from a mid-stage study of the drug.
Shares of Peregrine Pharmaceuticals Inc. sank Thursday after the drug developer said it will stop studying a treatment combination involving its potential lung cancer drug bavituximab.
THE SPARK: The Tustin, Calif., company said a combination of bavituximab, carboplatin and a chemotherapy drug labeled paclitaxel did not produce a meaningful enough difference in overall survival in patients compared with carboplatin and paclitaxel alone. The company had just completed an analysis of data from a mid-stage study of the drug.
No comments:
Post a Comment